Nimodipine Shortage: What Providers and Prescribers Need to Know in 2026

For neurocritical care specialists, neurosurgeons, neurologists, and hospital pharmacists managing patients with aneurysmal subarachnoid hemorrhage (aSAH), the availability of nimodipine is a clinical priority — not merely a logistical inconvenience. Nimodipine is the only FDA-approved oral agent for reducing the incidence and severity of ischemic deficits from vasospasm following aSAH, and its 21-day treatment window begins at the time of hemorrhage.

This guide consolidates everything prescribers and clinical teams need to know about the 2026 nimodipine supply situation, clinical workarounds, and how to help patients successfully complete their course of therapy — including after discharge.

Current FDA and ASHP Shortage Status

The FDA Drug Shortages database currently lists Nymalize (nimodipine) oral solution as in shortage. The ASHP has confirmed that multiple Nymalize oral solution formulations have been discontinued by Arbor Pharmaceuticals, including:

• Nymalize 30 mg/10 mL unit-dose cup (12-count carton) — discontinued
• Nymalize 60 mg/20 mL unit-dose cup (12-count carton) — discontinued
• Nymalize 60 mg/20 mL pint bottle (473 mL) — discontinued

The replacement formulation — Nymalize 6 mg/mL oral solution in 5 mL prefilled oral syringes — is FDA-approved and commercially available from Arbor Pharmaceuticals, but distribution has been intermittently disrupted. Generic nimodipine 30 mg capsules remain generally available at the national level, though individual pharmacy stock may vary.

Clinical Background: Why This Shortage Matters

The Neurocritical Care Society and major neurosurgical guidelines recommend nimodipine 60 mg orally (or via NG tube) every 4 hours for 21 days in all aSAH patients, regardless of Hunt and Hess grade. This is Level I evidence for a mortality and morbidity reduction. The drug's selectivity for cerebral vasculature — compared to systemic calcium channel blockers — underlies its unique therapeutic profile.

Because vasospasm risk peaks between days 3 and 14 post-hemorrhage, any interruption in nimodipine therapy during this window carries real clinical risk. Ensuring continuity of nimodipine through hospital discharge is a critical part of SAH management that should be actively planned — not left to chance.

Inpatient Management Strategies During Shortage

For patients requiring nasogastric or feeding tube administration when Nymalize oral solution is unavailable, the ASHP provides the following guidance:

1. Withdraw the liquid contents of one 30 mg nimodipine capsule using an 18-gauge needle and syringe.
2. Transfer the contents to an oral syringe that is not compatible with IV connections (critical safety requirement to prevent accidental IV administration).
3. Label the oral syringe clearly: "For Oral Use Only."
4. Administer via NG or feeding tube, then flush with 30 mL of 0.9% normal saline.

Critical safety reminder: Never administer nimodipine intravenously. The FDA boxed warning for nimodipine explicitly states that parenteral administration has caused deaths and serious adverse events. All clinical staff involved in nimodipine administration must be educated on this risk.

Discharge Planning: Ensuring Continuity of Nimodipine Therapy

Discharge planning for aSAH patients should include a specific protocol for nimodipine continuity. Key steps include:

• Verify outpatient pharmacy stock before discharge: Do not assume the patient's preferred pharmacy carries nimodipine. Verify in advance, or dispense from the hospital's outpatient pharmacy.
• Dispense enough supply at discharge: Calculate the number of days remaining in the 21-day course and ensure the patient leaves with a complete supply if possible, or with a verified pharmacy prescription in hand.
• Switch to generic capsules if appropriate: If the patient was on Nymalize oral solution inpatient but can swallow at discharge, switching to generic nimodipine 30 mg capsules is clinically appropriate and significantly easier to source.
• Recommend medfinder for providers: medfinder is a service that contacts pharmacies on behalf of patients to check for medication availability. Referring discharged SAH patients to medfinder can help ensure they locate nimodipine in stock quickly.

ENFit Compatibility Issue: A Practical Concern

One practical challenge with the new Nymalize prefilled syringe formulation is ENFit incompatibility. Hospitals transitioning to ENFit enteral connectors will find that the Nymalize oral syringe does not directly connect to ENFit feeding tubes. The prefilled syringe may need to be repackaged in an ENFit-compatible syringe for NG/tube administration. Pharmacy and nursing staff should be aware of this requirement when procuring and administering the new Nymalize formulation.

Resources for Clinical Teams

Clinical teams dealing with nimodipine supply challenges should bookmark:

• FDA Drug Shortages Database: https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
• ASHP Drug Shortage Detail for Nimodipine Oral Solution: https://www.ashp.org/drug-shortages/current-shortages
• medfinder for Providers: A service to help discharged patients locate nimodipine at local pharmacies.

Also see: How to Help Your Patients Find Nimodipine in Stock: A Provider's Guide.